Vaxcyte Inc [PCVX] stock is trading at $78.97, up 2.73%. An important factor to consider is whether the stock is rising or falling in short-term value. The PCVX shares have gain 4.93% over the last week, with a monthly amount glided 24.56%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 15, February 2024, Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024. In a post published today on Yahoo Finance, Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2023 after market close on February 27, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.
From an analyst’s perspective:
Vaxcyte Inc [NASDAQ: PCVX] stock has seen the most recent analyst activity on December 07, 2023, when Mizuho initiated its Buy rating and assigned the stock a price target of $69. On January 03, 2023, Needham reiterated its Buy rating and revised its price target to $58 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $66 on December 15, 2022. BTIG Research initiated its recommendation with a Buy and recommended $69 as its price target on November 17, 2022.
Vaxcyte Inc [PCVX] stock has fluctuated between $34.11 and $77.69 over the past year. Currently, Wall Street analysts expect the stock to reach $63.25 within the next 12 months. Vaxcyte Inc [NASDAQ: PCVX] shares were valued at $78.97 at the most recent close of the market. An investor can expect a potential drop of -19.91% based on the average PCVX price forecast.
Analyzing the PCVX fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 77.13 points at the first support level, and at 75.30 for the second support level. However, for the 1st resistance point, the stock is sitting at 80.21, and for the 2nd resistance point, it is at 81.46.
Vaxcyte Inc [PCVX] reported earnings per share of -$0.91 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.84/share, meaning a difference of -$0.07 and a surprise factor of -8.30%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.7 per share as compared to estimates of -$0.74 per share, a difference of $0.04 representing a surprise of 5.40%.
Ratios To Look Out For
For context, Vaxcyte Inc’s Current Ratio is 15.14. On the other hand, the Quick Ratio is 15.14, and the Cash Ratio is 0.05.
Transactions by insiders
The next item on our agenda is insider trading, which has seen 2 insider purchases totaling 19,900 shares and 2 insider sales totaling 15,000 shares over the past 3 months. Recent insider trading involved GUGGENHIME ANDREW, PRESIDENT AND CFO, that happened on Feb 20 when 8000.0 shares were sold. CHIEF OPERATING OFFICER, Wassil Jim completed a deal on Feb 01 to sell 3000.0 shares. Meanwhile, CHIEF EXECUTIVE OFFICER PICKERING GRANT sold 2616.0 shares on Feb 01.
